# **FIRST AMENDMENT TO AGREEMENT**

This first amendment to the Research Service Agreement by and between **Dewpoint Therapeutics, Inc**., with its registered seat at 451 D Street, Suite 104, Boston, MA 02210, U.S.A., registered in the State of Delaware **(“Company”)** and **Ústav molekulární genetiky AV ČR, v. v. i.** (in English commonly referred to as the Institute of Molecular Genetics of the Czech Academy of Sciences), with its registered seat at: Vídeňská 1083, 142 00 Prague 4, Czech Republic, Identification number: 68378050 **(“IMG”)** effective as of **September 9, 2024** (the “Agreement”), is entered into as of the date of its signature by the latter of both Parties (the amendment, “The First Amendment”).

In accordance with this Amendment, the parties hereby agree as follows:

1. Paragraph 2 of Article V of the Agreement is hereby amended and replaced in its entirety with:

“This Agreement is concluded for the period until 18 August 2025. The provisions concerning confidentiality, Intellectual Property protection and publications and warranties/liability shall survive the expiration and/or termination of this Agreement.”

1. Capitalized terms used and not otherwise defined herein shall have the respective meanings set forth in the Agreement.
2. All other terms and conditions of the Agreement not modified by this First Amendment shall remain in full force and effect.
3. The Agreement, as modified by this First Amendment, contains the entire understanding of the parties with respect to their subject matter.
4. This First Amendment becomes valid on the date of its signature by both Parties and its Effective Date is the day of its publication in the Czech public contract registry (https://smlouvy.gov.cz/) which will be carried out by IMG pursuant to Act No. 340/2015 Coll.
5. This First Amendment may be executed in two counterparts, each of which will be deemed an original, but both of which together shall constitute but one and the same instrument. Alternatively, it may be signed by both Parties with qualified electronic signatures, which shall constitute an original of this First Amendment.

 IN WITNESS WHEREOF, the parties have caused this First Amendment to be executed by their duly authorized representatives.

**DEWPOINT THERAPEUTICS, INC.** **[SIGNATORY INFORMATION]**

By: By:

Name: xxxxxxxxxxxxxxxxxxxx Name: xxxxxxxxxxxxxxxxxxxx

Title: director Title: \_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_

Date: Date: